 |
ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ — I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024.
Event Details
|
Meeting Date |
Thursday, November 7, 2024 |
|
Meetings |
One-on-one and small group meetings: November 7, 2024 |
|
Management |
Sean Fu, PhD, MBA, Interim Chief Executive Officer (CEO) Joe Skelton, Chief Financial Officer (CFO) Phillip Dennis, MD, PhD, Chief Medical Officer (CMO) Tyler Ehler, Senior Director, Investor Relations |
For more information, please contact your Truist Securities representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
View original content to download multimedia: Read More